everolimus
Not Tagged
['s0931', 'everest', 'improve']
#asco22: s0931 everest trial &gt;1,500 patients w hi-risk #kidneycancer: though many stopped tx early, adjuvant everolimus tended to lengthen rfs. results (p=0.025) just missed pre-specified 0.022 significance. rfs improved 21% in very hi-risk disease 
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.